Teva: "it was a wonderful year for the US generics with the launch of venlafaxine [effexor] that really gave us a push in profits and profitability. we're not going to see that kind of launch in 2011 but instead of that we're going to have a long list of much smaller products
lovenox should represent - even as a 3rd or 4th generic - a 400-500M product annually. this can't be that far off from what generic effexor brought in during the 6 months exclusivity in 2010, and would still have to represent one of the largest sellers among their US generics. to say flat out they won't have a new launch of a large selling product in the US generics business in 2010 but rather lots of much smaller product launches tells me they are not confident they will get approval for lovenox early this year
Market Data 
Markets 
AI
